ATGAM falls under the group of medications known as immunosuppressants (anti-rejection medicines). The ATGAM injection approval was taken place for use following a kidney transplant to keep the body from rejecting the kidney. This medicine is also used for treating aplastic anemia. ATGAM injection must strictly be administered under a doctor experienced with immunosuppressive therapy in the transplant setting. It is advised that patients should be closely and precisely monitored while on the infusion and until the end of the infusion.